ABBV - Spark Newswire

1 minute read

Here’s How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years

August 12, 12:01 PM

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 3.64% on an annualized basis producing an average annual return of 15.04%. Currently, AbbVie has a market capitalization of $250.56 billion.

ABBV

1 minute read

This Nasal Spray For Eye Disease Stock Is ‘Attractive’, Has Potential 160% Upside

By Vandana Singh

August 11, 3:11 PM

Chardan initiated coverage on Oyster Point Pharma Inc (NASDAQ:OYST) with a Buy rating and a price target of $22. The lead product,…

ABBV

4 minute read

Options

10 Health Care Stocks With Whale Alerts In Today’s Session

By Benzinga Insights

August 9, 1:38 PM

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

ABBV

2 minute read

Looking At AbbVie’s Recent Whale Trades

By Benzinga Insights

August 5, 12:38 PM

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 12 strange trades.

ABBV

2 minute read

Recession Investing: 5 High Yield Dividend Stocks For A Downturn

By Robert Kuczmarski

August 3, 2:23 PM

As the healthcare industry absorbed enormous amounts of profits during the Covid-19 pandemic, many healthcare companies will be increasing shareholder distributions to entice investors to buy their stock.

ABBV

1 minute read

FDA
News

AbbVie FDA Approves JUVÉDERM VOLUX XC For Improvement Of Jawline Definition

By Benzinga Newsdesk

August 3, 8:52 AM

Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM® VOLUX™ XC for the improvement of jawline definition in adults over the age of 21 with

ABBV

1 minute read

AbbVie, Sosei Build In 2020 Pact With New Neurological Disease-Focused Agreement

By Vandana Singh

August 2, 6:32 AM

Sosei Group Corporation and AbbVie Inc (NYSE:ABBV) announced a new drug discovery collaboration and option-to-license agreement to discover, develop and commercialize small molecules…

ABBV

2 minute read

News

Sosei Heptares and AbbVie Announced New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases; Sosei Heptares Eligible to Receive up to $80M in Upfront, Near-term Milestone Payments; Up to $1….

By Charles Gross

August 1, 7:18 PM

Sosei Group Corporation ("the Company"; TSE: 4565) and AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announce they have entered a new drug discovery collaboration and option-to-license agreement to discover, develop and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR)

ABBV